TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $43.00 at JPMorgan Chase & Co.

TG Therapeutics (NASDAQ:TGTX) had its price target boosted by stock analysts at JPMorgan Chase & Co. from $30.00 to $43.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 20.18% from the stock’s previous close.

Other equities research analysts also recently issued reports about the company. B. Riley upped their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. The Goldman Sachs Group upped their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. HC Wainwright lifted their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Finally, TD Cowen assumed coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target on the stock. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Price Performance

Shares of TGTX opened at $35.78 on Monday. TG Therapeutics has a one year low of $12.30 and a one year high of $36.50. The stock’s fifty day moving average is $25.62 and its 200-day moving average is $21.70. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a market capitalization of $5.57 billion, a price-to-earnings ratio of -357.76 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm’s quarterly revenue was down 49.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.73 EPS. Equities analysts anticipate that TG Therapeutics will post 0.17 EPS for the current year.

Insider Activity

In other news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now owns 100,195 shares of the company’s stock, valued at $3,049,935.80. This trade represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 10.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TGTX. Sei Investments Co. purchased a new stake in shares of TG Therapeutics during the first quarter worth $591,000. Russell Investments Group Ltd. grew its position in TG Therapeutics by 133.5% in the first quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company’s stock worth $796,000 after acquiring an additional 29,923 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of TG Therapeutics during the 1st quarter worth $91,000. Price T Rowe Associates Inc. MD raised its holdings in shares of TG Therapeutics by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,603 shares of the biopharmaceutical company’s stock valued at $1,303,000 after purchasing an additional 5,015 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in shares of TG Therapeutics by 29.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 524,861 shares of the biopharmaceutical company’s stock valued at $7,983,000 after purchasing an additional 120,699 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.